|  |  |
| --- | --- |
| Clone | EP266 |
| Source | Rabbit Monoclonal |
| Cat # | PR110-6ml RTU PR110-3ml RTU CR110-0.1ml Conc CR110-0.5ml Conc HAR110-3ml RTU HAR110-6ml RTU |
| Regulatory Status | IVD |

**Terminal deoxynucleotidyl transferase (TdT)- EP-266**

**Intended Use:**

This antibody is intended for use to qualitatively identify Terminal deoxynucleotidyl transferase (TdT)by light microscopy in formalin fixed, paraffin embedded tissue sections using immunohistochemical detection methodology. Interpretation of any positive or negative staining must be complemented with the evaluation of proper controls and must be made within the context of the patient’s clinical history and other diagnostic tests. A qualified pathologist must perform evaluation of the test.

**Summary and Explanation:**

Terminal deoxynucleotidyl transferase (TdT) is a unique DNA polymerase that changes the addition of deoxynucleoside 5’- triphosphate to the 3’-end of a DNA initiator without template direction. TdT contributes to the generation of junctional diversity in antigen receptors of immature lymphocytes.

TdT is expressed in lymphoid precursors of B- and T-cell lineage in thymus and bone marrow. Foci of TdT positive cells may be observed in peripheral lymphoid tissues. TdT is also present in malignant tumors of lymphoblastic lineage and thymoma. It is a sensitive and specific marker for lymphoblastic lymphoma/leukemia.

**Immunogen:**A synthetic peptide corresponding to residues of human TdT protein

**Isotype:** Rabbit IgG

**Reagent Provided:   
 Concentrated format:** Antibody to TdT is diluted in antibody diluent, with 1% bovine serum   
 albumin (BSA) and 0.05% sodium azide (NaN3). Recommended dilutions: 1:50-  
 1:100.  
 The antibody dilution and protocol may vary depending on the specimen   
 preparation and specific application. Optimal conditions should be   
 determined by individual laboratory.

**Pre-diluted format:** PathnSitu ready to use antibodies are pre tittered to optimal staining   
 conditions. Further dilution may loose the activity and may yield to sub   
 optimal staining.

**Storage Recommendations:** Store at 2°-8°C. Do not use after expiration date provided on the vial.

**Staining Recommendations:   
 Antigen Retrieval Solution:** Use **EDTA Bufferor Tris-EDTA(PathnSitu Cat # PS008/PS009)** as   
 antigen retrieval solution Heat Retrieval Method: Retrieve sections under   
 steam pressure for 15 min using PathnSitu’s MERS (Multi Epitope   
 Retrieval System) then allow solution to cool for 10 minutes then transfer   
 tissue sections/slides to distilled water.

**Primary Antibody:**  Cover the tissue sections with primary antibody and incubate for 30   
 min at room temperature when used PathnSitu PolyExcel Detection   
 System.

**Detection System:** Refer to PathnSitu PolyExcel detection system protocol or manufacturer’s detection kit staining protocol when used other vendor detection system.

**Cellular Localization:** Nucleus.

**Positive Control:** Thymoma, Thymus.

**Troubleshooting:** Follow the antibody specific protocol recommendations according to data sheet provided. If unusual results occur, contact PathnSitu Technical Support at 040-2701 5544 or techsupport@pathnsitu.com.

**Limitations and Warranty:** There are no warranties, expressed or implied, which extend beyond this   
 description. PathnSitu is not liable for property damage, personal injury, or   
 economic loss caused by this product.

**Bibliography:**  1. Maglott D*, et al.*: *Nucleic Acids Res* 2005, 33:D54-58   
2. Yang-Feng TL*, et al.*: *Cytogenet Cell Genet* 1986, 43:121-126   
3. Onciu M*, et al.*: *Am J Clin Pathol* 2002, 118:248-254   
4. Strauchen JA*, et al.*: *Am J Clin Pathol* 2001, 116:12-16   
5. Meru N*, et al.*: *Blood* 2002, 99:531-537   
6. Orazi A*, et al.*: *Mod Pathol* 1994, 7:582-586   
7. Orazi A*, et al.*: *Am J Clin Pathol* 1994, 102:640-645   
8. Bearman RM*, et al.*: *Am J Clin Pathol* 1981, 75:794-802

**TdT, EP266 antibody has been created by Epitomics Inc., using Epitomics’ proprietary rabbit monoclonal antibody technology covered under Patent No.’s 5,675,063 and 7,402,409.**